key: cord-0918035-3wv17uy0
authors: VanBlargan, Laura; Errico, John; Halfmann, Peter; Zost, Seth; Crowe, James; Purcell, Lisa; Kawaoka, Yoshihiro; Corti, Davide; Fremont, Daved; Diamond, Michael
title: An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
date: 2021-12-27
journal: Res Sq
DOI: 10.21203/rs.3.rs-1175516/v1
sha: a8e75fe0491002d94b47c3c11c2cb1aa42c507db
doc_id: 918035
cord_uid: 3wv17uy0

The emergence of the highly-transmissible B.1.1.529 Omicron variant of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody countermeasure efficacy because of the number of mutations in the spike protein. Here, we tested a panel of anti-receptor binding domain monoclonal antibodies (mAbs) corresponding to those in clinical use by Vir Biotechnology (S309, the parent mAb of VIR-7831 [Sotrovimab]), AstraZeneca (COV2–2196 and COV2–2130, the parent mAbs of AZD8895 and AZD1061), Regeneron (REGN10933 and REGN10987), Lilly (LY-CoV555 and LY-CoV016), and Celltrion (CT-P59) for their ability to neutralize an infectious B.1.1.529 Omicron isolate. Several mAbs (LY-CoV555, LY-CoV016, REGN10933, REGN10987, and CT-P59) completely lost neutralizing activity against B.1.1.529 virus in both Vero-TMPRSS2 and Vero-hACE2-TMPRSS2 cells, whereas others were reduced (COV2–2196 and COV2–2130 combination, ~12-fold decrease) or minimally affected (S309). Our results suggest that several, but not all, of the antibodies in clinical use may lose efficacy against the B.1.1.529 Omicron variant.

Since December of 2019, the global COVID-19 pandemic caused by SARS-CoV-2 has resulted in 267 million infections and 5.3 million deaths. The expansion of the COVID-19 pandemic and its accompanying morbidity, mortality, and destabilizing socioeconomic effects have made the development and distribution of SARS-CoV-2 therapeutics and vaccines an urgent global health priority 1 . While the rapid deployment of countermeasures including monoclonal antibodies and multiple highly effective vaccines has provided hope for curtailing disease and ending the pandemic, this has been jeopardized by emergence of more transmissible variants with mutations in the spike protein that also could evade protective immune responses. with pseudoviruses or authentic SARS-CoV-2 strains suggest that neutralization by many EUA mAbs might be diminished against some of these variants, especially those containing mutations at positions L452, K477, and E484 [2] [3] [4] [5] [6] . Notwithstanding this, in vivo studies in animals showed that when most EUA mAbs were used in combination they retained e cacy against different variants 7 . The recent emergence of B.1.1.529, the Omicron variant 8, 9 , which has a larger number of mutations (~30 substitutions, deletions, or insertions) in the spike protein, has raised concerns that this variant will escape from protection conferred by vaccines and therapeutic mAbs.

We obtained an infectious clinical isolate of B.1.1.529 from a symptomatic individual in the United States (hCoV-19/USA/WI-WSLH-221686/2021). We propagated the virus once in Vero cells expressing transmembrane protease serine 2 (TMPRSS2) to prevent the emergence of adventitious mutations at or near the furin cleavage site in the spike protein 10 . Our B.1.1.529 isolate encodes the following mutations in the spike protein (A67V, D69-70, T95I, G142D, D143-145, D211, L212I, insertion 214EPE, G339D, S371L,  S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H,   T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, and L981F; Fig 1ab and GISAID: EPI_ISL_7263803) , which is similar to strains identi ed in Africa 11 . Our isolate, however, lacks an R346K mutation, which is present in a minority (~8%) of reported strains.

Given the number of substitution in the B.1.1.529 spike protein, including eight amino acid changes (K417N, G446S, S477N, Q493R, G496S, Q498R, N501Y, Y505H) in the ACE2 receptor binding motif (RBM), we rst evaluated possible effects on the structurally-de ned binding epitopes 12 16 ; REGN10933 (RBD group I) and REGN10987 (RBD group III) 17 , LY-CoV555 (RBD group I) and LY-CoV016 (RBD group I) 18, 19 ; and CT-P59 [Celltrion, RBD group I] 20 ) along with an additional broadly neutralizing mAb (SARS2-38, (RBD group II)) that we recently described 21 . We mapped the B.1.1.529 spike mutations onto the antibody-bound SARS-CoV-2 spike or RBD structures published in the RCSB Protein Data Bank (Fig 1c-k) . While every antibody analyzed had structurally de ned recognition sites that were altered in the B.1.1.529 spike, the differences varied among mAbs with some showing larger numbers of changed residues (Fig 1l: COV2 -2196, n = 5; COV2-2130, n = 4; S309, n = 2; REGN10987, n = 4; REGN10933, n = 8; Ly-CoV555, n = 2; Ly-CoV016, n = 6; CT-P59, n = 8; and SARS2-38, n = 2).

To address the functional signi cance of the spike sequence variation in B.1.1.529 for antibody neutralization, we used a high-throughput focus reduction neutralization test (FRNT) 22 whereas COV2-2130/COV2-2196 showed a ~12-fold (P < 0.0001) reduction in inhibitory activity from an EC 50 of 12 to 147 ng/mL.

We repeated experiments in Vero-hACE2-TMPRSS2 cells to account for effects of hACE2 expression, which can affect neutralization by some anti-SARS-CoV-2 mAbs 21, 24 . Moreover, modeling studies suggest that the mutations in the B.1.1.529 spike may enhance interactions with hACE2 25 . All individual or combinations of mAbs tested neutralized the WA1/2020 D614G isolate as expected. However, REGN10933, REGN10987, LY-CoV555, LV-CoV016, SARS2-38, and CT-P59 completely lost neutralizing activity against B.1.1.529, and the combinations of REGN10933/ REGN10987 or LY-CoV555/LV-CoV016 also lacked inhibitory capacity (Fig 3a-h) . In comparison, COV2-2130 and COV2-2196 showed reduced activity (~12 and 16-fold, respectively; P < 0.0001) against B.1.1.529 as did the combination of COV2-2130/COV2-2196 mAbs (~11-fold, P < 0.0001). The S309 mAb exhibited less potent neutralizing activity in Vero-hACE2-TMPRSS2 cells against WA1/2020 D614G virus with a atter dose response curve (Fig   3d) , as seen previously 6, 26 , and showed a moderate (~6-fold, P < 0.0001) reduction in neutralizing activity against B.1.1.529. Thus, while the trends in mAb neutralization of B.1.1.529 generally were similar to Vero-TMPRSS2 cells, some minor differences in potency were noted in cells expressing hACE2.

Our experiments show a marked loss of inhibitory activity by several of the most highly neutralizing mAbs that are in advanced clinical development or have EUA approval. We evaluated antibodies that correspond to monotherapy or combination therapy that have shown pre-and post-exposure success in clinical trials and patients infected with historical SARS-CoV-2 isolates. Our results con rm in silico predictions of how amino acid changes in B.1.1.529 RBD might negatively impact neutralizing antibody interactions 18, 27 . Moreover, they agree with preliminary studies showing that several clinically used antibodies lose neutralizing activity against B.1.1.529 spike-expressing recombinant lentiviral or vesicular stomatitis virus (VSV)-based pseudoviruses [28] [29] [30] . One difference is that our study with authentic B.1.1.529 showed only moderately reduced neutralization by antibodies corresponding to the AstraZeneca combination (COV2-2196 and COV2-2130); in contrast, another group reported escape of these mAbs using a VSV pseudovirus displaying a B.1.1.529 spike protein in Huh7 hepatoma cells 29 . Additional studies are needed to determine whether this disparity in results is due to the cell type, the virus (authentic versus pseudotype), or preparation and combination of antibody. To begin to address this issue, we obtained AZD1061, AZD8895, and the combination AZD7442 directly from the manufacturer and tested them for neutralization of WA1/2020 D614G and B.1.1529 in Vero-hACE2-TMPRSS2 cells. We observed relatively similar reductions in inhibitory activity compared to the preclinical COV2-2130 and COV2-2196 mAbs with 49, 92, and 33-fold lower EC 50 values against B.1.1.529 by AZD1061, AZD8895, and AZD7442, respectively (Fig 3g, i, and j) .

While the Regeneron (REGN10933 and REGN10987), Lilly (LY-CoV555 and LV-CoV016) and Celltrion (CT-P59) antibodies or combinations showed an almost complete loss of neutralizing activity against B.1.1.529, in our assays with Vero-TMPRSS2 and Vero-hACE2-TMPRSS2 cells, the mAbs corresponding to the AstraZeneca combination (COV-2196 and COV-2130) or Vir Biotechnology (S309) products retained substantial inhibitory activity. Although these data suggest that some of mAbs in clinical use may retain bene t, validation experiments in vivo 7 are needed to support this conclusion and inform clinical decisions.

Given the loss of inhibitory activity against B.1.1.529 of many highly neutralizing anti-RBD mAbs in our study, it appears likely that serum polyclonal antibody responses generated after vaccination or natural infection also may lose substantial inhibitory activity against B.1.1.529, which could compromise protective immunity and explain a rise in symptomatic infections in vaccinated individuals 31 In summary, our cell culture-based analysis of neutralizing mAb activity against an authentic infectious B.1.1.529 Omicron SARS-CoV-2 isolate suggests that several, but not all, existing therapeutic antibodies will lose protective bene t. Thus, the continued identi cation and use of broadly and potently neutralizing mAbs that target the most highly conserved residues on the SARS-CoV-2 spike likely is needed to prevent resistance against B.1.1.529 and future variants with highly mutated spike sequences. Monoclonal antibody puri cation. The mAbs used in this paper (COV2-2196, COV2-2130, S309, REGN10933, REGN10987, LY-CoV555, LY-CoV016, CT-P59, SARS2-38, AZD1061, AZD8895, and AZD7442) have been described previously 14, 17, 21, [44] [45] [46] [47] [48] . S309 is the parent of VIR-7831 (Sotrovimab); the clinically used mAb is engineered for enhanced clinical developability, as reported previously 23 . COV2-2196 and COV2-2130 mAbs were produced after transient transfection using the Gibco ExpiCHO Expression System (ThermoFisher Scienti c) following the manufacturer's protocol. Culture supernatants were puri ed using HiTrap MabSelect SuRe columns (Cytiva, formerly GE Healthcare Life Sciences) on an AKTA Pure chromatographer (GE Healthcare Life Sciences). Puri ed mAbs were buffer-exchanged into PBS, concentrated using Amicon Ultra-4 50-kDa centrifugal lter units (Millipore Sigma) and stored at -80 °C until use. Puri ed mAbs were tested for endotoxin levels (found to be less than 30 EU per mg IgG).

Endotoxin testing was performed using the PTS201F cartridge (Charles River), with a sensitivity range from 10 to 0.1 EU per mL, and an Endosafe Nexgen-MCS instrument (Charles River). S309, REGN10933, REGN10987, LY-CoV016, LY-CoV555, CT-P59, and SARS2-38 mAb proteins were produced in CHOEXPI or EXPI293F cells and a nity puri ed using HiTrap Protein A columns (GE Healthcare, HiTrap mAb select Xtra #28-4082-61). Puri ed mAbs were suspended into 20 mM histidine, 8% sucrose, pH 6.0 or PBS. The 

This is a list of supplementary les associated with this preprint. Click to download.

NMEDA117423ASourceDataFigure3.xlsx

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

In vivo monoclonal antibody e cacy against SARS-CoV-2 variant strains

How bad is Omicron? What scientists know so far

Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear

Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis

B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Potently neutralizing and protective human antibodies against SARS-CoV-2

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein

A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope

Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2

The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv

Neutralizing and protective human monoclonal antibodies recognizing the Nterminal domain of the SARS-CoV-2 spike protein

The Omicron Variant Increases the Interactions of SARS-CoV-2 Spike Glycoprotein with ACE2. bioRxiv

Lectins enhance SARS-CoV-2 infection and in uence neutralizing antibodies

Predictions of the SARS-CoV-2 Omicron Variant (B.1.1.529) Spike Protein Receptor-Binding Domain Structure and Neutralizing Antibody Interactions. bioRxiv

Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies. medRxiv : the preprint server for health sciences

B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes. bioRxiv

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. bioRxiv

Omicron likely to weaken COVID vaccine protection

SARS-CoV-2 Omicron has extensive but incomplete escape of P zer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv : the preprint server for health sciences

Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by postimmunisation serum. medRxiv : the preprint server for health sciences

Looking beyond COVID-19 vaccine phase 3 trials

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

r) New Perspective on SARS-CoV-2 Biology

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Vero-TMPRSS2 41 and Vero-hACE2-TMPRSS2 6 cells were cultured at 37°C in Dulbecco's Modi ed Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES pH

U/ml of penicillin-streptomycin. Vero-TMPRSS2 cells were supplemented with 5 mg/mL of blasticidin. Vero-hACE2-TMPRSS2 cells were supplemented with 10 µg/mL of puromycin. All cells routinely tested negative for mycoplasma using a PCR-based assay

The B.1.1.529 isolate (hCoV-19/USA/WI-WSLH-221686/2021) was obtained from an individual in Wisconsin as a midturbinate nasal swab and passaged once on Vero-TMPRSS2 cells 43 . All viruses were subjected to next-generation sequencing (GISAID: EPI_ISL_7263803) to con rm the stability of substitutions

Epitope footprints used in the multiple sequence alignment were determined using PISA interfacial analysis on the various mAb:RBD complexes 50 . Structural gures were generated using UCSF ChimeraX 51

All data supporting the ndings of this study are available within the paper, in the Source Data, and from the corresponding author upon request. There are no restrictions in obtaining access to primary data

No code was used in the course of the data acquisition or analysis

All reagents described in this paper are available through Material Transfer Agreements. AZD8895 and AZD1061 may be obtained from AstraZeneca for non-commercial internal research purposes under material transfer agreements upon request

The number of independent experiments and technical replicates used are indicated in the relevant Figure legends. A two-way ANOVA with Sidak's post-test was used for comparisons of

TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes

Spike mutation D614G alters SARS-CoV-2 tness

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

Rapid isolation and pro ling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Identi cation of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Inference of macromolecular assemblies from crystalline state

Meeting modern challenges in visualization and analysis

For data with mAb combinations, the x-axis represents the total concentration of mAb used. One representative experiment of three performed in technical duplicate is shown. Error bars indicate range of technical replicates. Data (% relative infection) are normalized to a no mAb control. g, Summary of EC 50 values (ng/ml) of neutralization of SARS-CoV-2 viruses

Data is the geometric mean of 3 experiments. Blue shading: light

ng/mL; dark, EC 50 > 10,000 ng/mL. h, Comparison of EC 50 values by mAbs against WA1

Each symbol represents neutralization data from an individual experiment. Bars indicate mean values. The dotted line indicates the upper limit of dosing of the assay

. We thank Rachel Nargi, Robert Carnahan, Tiong Tan, and Lisa Schimanski for assistance and generosity with mAb generation and puri cation, and Samuel A.